Гиперсимпатикотония в патогенезе артериальной гипертонии и методы ее коррекции. Часть II
https://doi.org/10.15829/1728-8800-2021-2845
Аннотация
Во второй части обзора рассмотрены различные классы препаратов, которые влияют на артериальное давление при повышении тонуса симпатической нервной системы. Обсуждаются дополнительные возможности того, как уменьшить негативное влияние активности симпатической нервной системы на сердечно-сосудис-тую систему и улучшить прогноз.
Об авторах
А. С. Сафарян
ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава России
Россия
Россия
Кандидат медицинских наук, ведущий научный сотрудник отдела профилактики метаболических нарушений.
Москва, Тел.: +7 (903) 971-02-20
Д. В. Небиеридзе
ФГБУ Национальный медицинский исследовательский центр терапии и профилактической медицины Минздрава России
Россия
Россия
Доктор медицинских наук, руководитель отдела профилактики метаболических нарушений.
Москва
Список литературы
1. Сафарян А. С., Саргсян В. Д. Гиперсимпатикотония в патогенезе артериальной гипертонии и методы ее коррекции. Часть I. Кардиоваскулярная терапия и профилактика. 2020;19(6):2693. https://doi.org/10.15829/1728-8800-2020-2693.
2. Noll G, Wenzel RR, Schneider M, et al. Increased activation of sympathetic nervous system and endothelin by mental stress in normotensive offspring of hypertensive parents. Circulation. 1996;93(5):866-9. https://doi.org/10.1161/01.cir.93.5.866.
3. Saxena T, Azeema O, Saxena M. Pathophysiology of essential hypertension: an update. Expert Rev Cardiovasc Ther. 2018;16(12):879-87. https://doi.org/10.1080/14779072.2018.1540301.
4. Converse RJ, Jacobsen TN, Toto RD, et al. Sympathetic overactivity in patients with chronic renal failure. N Engl J Med. 1992;327(27):1912-8. https://doi.org/10.1056/NEJM199212313272704.
5. Артериальная гипертензия у взрослых. Клинические рекомендации 2020. Российский кардиологический журнал. 2020;25(3):3786. https://doi.org/10.15829/1560-4071-2020-3-3786.
6. Рипп Т . М ., Мордовин В. Ф. Рекомендации Европейского общества кардиологов и Европейского общества артериальной гипертензии 2018 года о новых методах лечения гипертензий - “DEVICE-BASED TREATMENT”. Артериальная гипертензия. 2018;24(6):623-7. https://doi.org/10.18705/1607-419X-2018-24-6-623-627.
7. Wray DW, Supiano MA. Impact of aldosterone receptor blockade compared with thiazide therapy on sympathetic nervous system function in geriatric hypertension. Hypertension. 2010;55(5):1217-23. https://doi.org/10.1161/HYPERTENSIONAHA.109.147058.
8. Ohlstein EH, Brooks DP, Feuerstein GZ, Ruffolo RR. Inhibition of sympathetic outflow by the angiotensin II receptors antagonist, eprosartan, but not by losartan, valsartan or irbesartan: relationship to differences in prejunctional angiotensin II receptor blocade. Pharmacology. 1997;55(5):244-51. https://doi.org/10.1159/000139534.
9. Rupp H, Maisch B, Brill CG. Drug withdrawal and rebound hypertension: differential action of the central antihypertensive drugs moxonidine and clonidine. Cardiovasc Drugs Ther. 1996;10 (Suppl 1):251-62. https://doi.org/10.1007/BF00120495.
10. Bohmann C, Schollmeyer P, Rump LC. Effects of imidazolines on noradrenaline release in rat isolated kidney. Naunyn Schmiedeberg‘s Arch Pharmacol. 1994;349:118-24.
11. Michel MC, Brodde OE, Schnepel B, et al. [3H]idazoxan and some other alpha 2-adrenergic drugs also bind with high affinity to a nonadrenergic site. Mol Pharmacol. 1989;35(3):324-30.
12. The Multicenter Diltiazem Postinfarction Trial Research Group. The effect of diltiazem on mortality and reinfarction after myocardial infarction. The Multicenter Diltiazem Postinfarction Trial Research Group. N Engl J Med. 1988;319(7):385-92. https://doi.org/10.1056/NEJM198808183190701.
13. Bousquet P, Hudson A, Jesús A García-Sevilla, Jun-Xu Li. Imidazoline Receptor System: The Past, the Present, and the Future. Pharmacol Rev. 2020;72(1):50-79. https://doi.org/10.1124/pr.118.016311.
14. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Клинические рекомендации. Под ред. Дедова И. И., Шестаковой М.В . 8-й вып. Сахарный диабет. 2017. 112 с. ISBN: 978-5-91487-090-1. https://doi.org/10.14341/DM20171S8.
15. Ernsberger P, Haxhiu MA, Graff LM, et al. A novel mechanism of action for hypertension control: moxonidine as a selective I1-imidazoline agonist. Cardiovasc Drugs Ther. 1994;8(Suppl 1):27-41. https://doi.org/10.1007/BF00877082.
16. Kuppers HE, Jaeger BA, Luszick JH, Grave MA, et al. Placebo-controlled comparison of the efficacy and tolerability of once-daily moxonidine and enalapril in mild-to-moderate essential hypertension. J Hypertens. 1997;15(1):93-7. https://doi.org/10.1097/00004872-199715010-00010.
17. McKaigue JP, Harron DW. The effects of rilmenidine on tests of autonomic function in humans. Clin Pharmacol Ther. 1992;52(5):511-7. https://doi.org/10.1038/clpt.1992.179.
18. Reid JL, Panfilov V, MacPhee G, Elliot HL. Clinical pharmacology of drugs acting on imidazoline and adrenergic receptors. Studies with clonidine, moxonidine, rilmenidine, and atenolol. Ann NY Acad Sci. 1995;763:673-8. https://doi.org/10.1111/j.1749-6632.1995.tb32461.x.
19. Deinum J, Riksen NP, Lenders JW. Pharmacological treatment of aldosterone excess. Pharmacol Ther. 2015;154:120-33. https://doi.org/10.1016/j.pharmthera.2015.07.006.
20. Cody RJ. The sympathetic nervous system and the renin-angiotensin-aldosterone system in cardiovascular disease. Am J Cardiol. 1997;80(9B):9J-14. https://doi.org/10.1016/s0002-9149(97)00832-1.
21. Funder JW, Carey RM, Fardella C, et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2008;93(9):3266-81. https://doi.org/10.1210/jc.2008-0104.
22. Pratt-Ubunama MN, Nishizaka MK, Boedefeld RL, et al. Plasma aldosterone is related to severity of obstructive sleep apnea in subjects with resistant hypertension. Chest. 2007;131(2):453-9. https://doi.org/10.1378/chest.06-1442.
23. Jeunemaitre X, Chatellier G, Kreft-Jais C, et al. Efficacy and tolerance of spironolactone in essential hypertension. Am J Cardiol. 1987;60(10):820-5. https://doi.org/10.1016/0002-9149(87)91030-7.
24. Krum H, Nolly H, Workman D, et al. Efficacy of eplerenone added to renin-angiotensin blockade in hypertensive patients. Hypertension. 2002;40(2):117-23. https://doi.org/10.1161/01.hyp.0000025146.19104.fe.
25. Pitt B, Reichek N, Willenbrock R, et al. Effects of eplerenone, enalapril, and eplerenone/enalapril in patients with essential hypertension and left ventricular hypertrophy: the 4E-left ventricular hypertrophy study. Circulation. 2003;108(15):1831-8. https://doi.org/10.1161/01.CIR.0000091405.00772.6E.
26. Strauch B, Zelinka T, Hampf M, et al. Prevalence of primary hyperaldosteronism in moderate to severe hypertension in the Central Europe region. J Hum Hypertens. 2003;17(5):349-52. https://doi.org/10.1038/sj.jhh.1001554.
27. Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Cha- racterization of resistant hypertension: association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. Arch Intern Med. 2008;168(11):1159-64. https://doi.org/10.1001/archinte.168.11.1159.
28. Gaddam K, Corros C, Pimenta E, et al. Rapid reversal of left ventricular hypertrophy and intracardiac volume overload in patients with resistant hypertension and hyperaldosteronism: a prospective clinical study. Hypertension. 2010;55(5):1137-42. https://doi.org/10.1161/HYPERTENSIONAHA.109.141531.
29. Dahal K, Kunwar S, Rijal J, et al. The effects of aldosterone antagonists in patients with resistant hypertension: a meta-analysis of randomized and nonrandomized studies. Am J Hypertens. 2015; 28(11):1376-85. https://doi.org/10.1093/ajh/hpv031.
30. Calhoun DA, White WB. Effectiveness of the selective aldosterone blocker, eplerenone, in patients with resistant hypertension. J Am Soc Hypertens. 2008;2(6):462-8. https://doi.org/10.1016/j.jash.2008.05.005.
31. Williams B, MacDonald TM, Caulfield M, et al. Prevention And Treatment of Hypertension With Algorithm-based therapy (PATHWAY) number 2: protocol for a randomised crossover trial to determine optimal treatment for drug-resistant hypertension. BMJ Open. 2015;5(8):e008951. https://doi.org/10.1136/bmjopen-2015-008951.
32. Pelliccia F, Rosano G, Patti G, et al. Efficacy and safety of mineralocorticoid receptors in mild to moderate arterial hypertension. Int J Cardiol. 2015;200:8-11. https://doi.org/10.1016/j.ijcard.2014.10.150.
33. The CAPRICORN investigators. Effect of carvedilol on outcome after myocardial infarction in patients with left ventricle dysfunction: the CAPRICORN randomized trial. Lancet. 2001;357(9266):1385-90. https://doi.org/10.1016/s0140-6736(00)04560-8.
34. Schaefers RF, Nuernberger J, Herrmann B, et al. Adrenoceptors mediating the cardiovascular and metabolic effects of alpha-methylnoradrenaline in man. J Pharmacol Exp Ther. 1999;289(2):918-25.
35. López-Sendón J, Swedberg K, McMurray J, et al. The Task Force on Beta-Blockers of the European Society of Cardiology. Expert consensus document on b-adrenergic receptor blockers. Eur Heart J. 2004;25(15):1341-62. https://doi.org/10.1016/j.ehj.2004.06.002.
36. Подзолков В. И., Осадчий К. К. Бета адреноблокаторы: взгляд XXI века. Русский медицинский журнал. 2006;14(10):737-42.
37. Freemantle N, Cleland J, Young P, et al. Beta blockade after myocardial infarction. Systematic review and meta regression analysis. BMJ. 1999;318(7200):1730-7. https://doi.org/10.1136/bmj.318.7200.1730.
38. Конкор (Бисопролол): Монография по продукту. М.: РКИ Соверо пресс, 2002 (ОАО Рекламфильм). с. 111. ISBN: 5-900126-75-7.
39. Xiang S, Zhang N, Yang Z, et al. Achievement of a target dose of bisoprolol may not be a preferred option for attenuating pressure overload-induced cardiac hypertrophy and fibrosis. Exper Ther Med. 2016;12(4):2027-38. https://doi.org/10.3892/etm.2016.3570.
40. Schlaich MP, Kaye DM, Lambert E, et al. Relation between cardiac sympathetic activity and hypertensive left ventricular hypertrophy. Circulation. 2003;108(5):560-5. https://doi.org/10.1161/01.CIR.0000081775.72651.B6.
41. Fukui M, Goda A, Komamura K, et al. Changes in collagen metabolism account for ventricular functional recovery following betablocker therapy in patients with chronic heart failure. Heart Vessels. 2016;31(2):173-82. https://doi.org/10.1007/s00380-014-0597-1.
42. Fumagalli C, Maurizi N, Marchionni N, Fornasari D. β-blo- ckers: Their new life from hypertension to cancer and migraine. Pharmacol Res. 2020;151:104587. https://doi.org/10.1016/j.phrs.2019.104587.
43. Hocht C, M Bertera F, S Del Mauro J, et al. What is the Real Efficacy of Beta-Blockers for the Treatment of Essential Hypertension? Curr Pharm Des. 2017;23(31):4658-77. https://doi.org/10.2174/1381612823666170608085109.
44. Lopez LM, Thorman AD, Mehta JL. Effects of amlodipine on blood pressure, heart rate, catecholamines, lipids and response to adrenergic stimulus. Am J Cardiol. 1990;66(17):1269-71. https://doi.org/10.1016/0002-9149(90)91118-p.
45. Wenzel RR, Allegranza G, Binggeli C, et al. Differential activation of cardiac and peripheral sympathetic nervous system by nifedipine: role of pharmacokinetics. J Am Coll Cardiol. 1997;29(7):1607-14. https://doi.org/10.1016/s0735-1097(97)00095-8.
46. Julius S. Effect of sympathetic overactivity on cardiovascular prognosis in hypertension. Eur Heart J. 1998;19 (Suppl. F):F14-8.
47. Марцевич С. Ю . Роль антагонистов кальция в современном лечении сердечно-сосудистых заболеваний. Русский медицинский журнал. 2003;11(9):539-41.
48. Dalhof B, Pennert K, Hansson L. Reversal of left ventricular hypertrophy in hypertensive patients. A metaanalysis of 109 treatment studies. Am J Hypertens. 1992;5(2):95-110. https://doi.org/10.1093/ajh/5.2.95.
49. Tschudi MR, Criscione L, Novosel D, et al. Antihypertensive therapy augments endothelium-dependent relaxations in coro- nary arteries of spontaneously hyp ertensive rats. Circulation. 1994;89:2212-8. https://doi.org/10.1161/01.cir.89.5.2212.
50. Neumann J, Ligtenberg G, Oey L, et al. Moxonidine normalizes sympathetic hyperactivity in patients with eprosartan-treated chronic renal failure. J Am Soc Nephrol. 2004;15(11):2902-7. https://doi.org/10.1097/01.ASN.0000143471.10750.8C.
51. Kailasam MT, Parmer RJ, Cervenka JH, et al. Divergent effects of dihydropyridine and phenylalkylamine calcium channel antagonists classes on autonomic function in human hypertension. Hypertension. 1995;26(1):143-9. https://doi.org/10.1161/01.hyp.26.1.143.
52. Saxena PR. Interaction between the renin-angiotensin-aldosterone and sympathetic nervous systems. J Cardiovasc Pharmacol 1992; 19(Suppl 6):S80-8. https://doi.org/10.1097/00005344-199219006-00013.
53. Lacourciere Y, Brunne H, Irwin R, et al. Group at LcS. Effects of modulation of the renin-angiotensin-aldosterone system on cough. J Hypertens. 1994;12:1387-93.
54. Noll G, Wenzel RR, de Marchi S, Shaw S, et al. Differential effects of captopril and nitrates on muscle sympathetic nerve activity in volunteers. Circulation. 1997;95(9):2286-92. https://doi.org/10.1161/01.cir.95.9.2286.
55. Kober L, Torp-Pederson C, Carlsen JE, et al. A clinical trial of the angiotensin-converting enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocyrdial infarction. Trandolapril Cardiac Evaluation (TRACE) Study Group. N Engl J Med. 1995;333(25):1670-6. https://doi.org/10.1056/NEJM199512213332503.
56. Miura S, Ideishi M, Sakai T, et al. Angiotensin II formation by an alternative pathway during exercise in humans. J Hypertens. 1994;12:1177-81.
57. Urata H, Strobel F, Ganten D. Widespread tissue distribution of human chymase. J Hypertens. 1994;12(Suppl 1):17-22.
58. Dominiak P. Modulation of sympathetic control by ACE inhibitors. Eur Heart J. 1994;14(Suppl 1):169-72.
59. Pitt B, Segal R, Martinez FA, et al. Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study). Lancet. 1997;349(9054):747-52. https://doi.org/10.1016/s0140-6736(97)01187-2.
60. Rump LC, Oberhauser V, Schwertfeger E, Schollmeyer P. Experimental evidence to support ELITE. Lancet. 1998;351:644-5. https://doi.org/10.1016/S0140-6736(05)78427-0.
61. Громова О. А ., Трошин И. Ю . Магний и “болезни цивилизации”: практическое руководство. Издательство: ГЭОТАР-Медиа; 2018. с. 800. ISBN: 978-5-9704-4527-3.
62. Сафарян А. С ., Саргсян В . Д ., Камышова Т . В . и др. Роль магния в развитии сердечно-сосудистой патологии и возможности ее предотвращения и коррекции препаратами магния (Часть 1). Рациональная Фармакотерапия в Кардиологии. 2019;15(5):725-35. https://doi.org/10.20996/1819-6446-2019-15-5-725-735.
63. Сафарян А . С ., Саргсян В . Д ., Небиеридзе Д . В . Роль магния в развитии сердечно-сосудистой патологии и возможности ее предотвращения и коррекции препаратами магния (Часть 2). Рациональная Фармакотерапия в Кардиологии. 2020;16(3):457-64. https://doi.org/10.20996/1819-6446-2020-02-16.
64. Громова О .А, Калачева А .Г, Сатарина Т . Е . и др. Влияние препарата Магне В6 на параметр ы стресса и когнитивную функцию при высоких психоэмоцион альных нагрузках. Трудный пациент. 2008;6(12):28-32.
65. Ноговицина О . Р ., Левитина Е . В . Неврологический аспект клиники, патофизиологии и коррекции нарушений при синдроме дефицита внимания. Журнал неврологии и психиатрии им. С. С . К орсакова. 2006;2:65-7.
Дополнительные файлы
Рецензия
Для цитирования:
Сафарян А.С., Небиеридзе Д.В. Гиперсимпатикотония в патогенезе артериальной гипертонии и методы ее коррекции. Часть II. Кардиоваскулярная терапия и профилактика. 2021;20(6):2845. https://doi.org/10.15829/1728-8800-2021-2845
For citation:
Safaryan A.S., Nebieridze D.V. Sympathetic hyperactivity in patients with hypertension: pathogenesis and treatment. Part II. Cardiovascular Therapy and Prevention. 2021;20(6):2845. (In Russ.) https://doi.org/10.15829/1728-8800-2021-2845
Просмотров:
677
ISSN 1728-8800 (Print)
ISSN 2619-0125 (Online)
ISSN 2619-0125 (Online)
Послать статью по эл. почте 
